Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Itolizumab (Primary) ; Corticosteroids
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Acronyms EQUATOR
  • Sponsors Equillium

    • Most Recent Events

    • 19 Aug 2024 Planned End Date changed from 1 Jul 2025 to 1 Dec 2025.
    • 19 Aug 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Dec 2024.
    • 08 Aug 2024 According to an Equillium media release, company announced a positive interim review of the study by the Independent Data Monitoring Committee, which raised no safety or futility concerns and recommended that the study proceed as planned

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top